Neuron BPh and Ferrer sign a framework agreement for the future development of joint projects.
The biotech company Neuron BPh and Ferrer, the biopharmaceutical group, have signed a medium- to long-term agreement for the co-development of projects based on mutual access to their compound collections. Both companies will include these compounds in their pharma-development programmes for the treatment of Alzheimer’s disease, insomnia and bacterial infections.
The heads of research of both companies have given the go-ahead to this agreement and are confident that it will lead to productive results in 2011.
The Biopharma division of Neuron BPh is working on the discovery of neuroprotective compounds and has a wide range of technologies at its disposal for testing the effectiveness of the compounds in question.
Ferrer is engaged in the development of compounds for the treatment of sleep disorders, as well as treatments against bacterial infections.
The increase in the number of potentially interesting pharmaceutical compounds available for study by both companies under the aegis of this agreement will enhance the possibilities of their success in finding novel treatments for these illnesses.